Voya Investment Management LLC Acquires 11,686 Shares of Omnicell, Inc. (OMCL)
Voya Investment Management LLC increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 443,319 shares of the company’s stock after acquiring an additional 11,686 shares during the quarter. Voya Investment Management LLC owned about 1.18% of Omnicell worth $19,107,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Pinebridge Investments L.P. grew its stake in Omnicell by 1.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock valued at $211,000 after acquiring an additional 76 shares in the last quarter. Arizona State Retirement System raised its holdings in Omnicell by 0.5% in the 2nd quarter. Arizona State Retirement System now owns 19,384 shares of the company’s stock valued at $835,000 after acquiring an additional 100 shares during the last quarter. Monroe Bank & Trust MI raised its holdings in Omnicell by 0.3% in the 1st quarter. Monroe Bank & Trust MI now owns 34,831 shares of the company’s stock valued at $1,416,000 after acquiring an additional 116 shares during the last quarter. Texas Permanent School Fund raised its holdings in Omnicell by 0.5% in the 1st quarter. Texas Permanent School Fund now owns 26,756 shares of the company’s stock valued at $1,088,000 after acquiring an additional 122 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its holdings in Omnicell by 2.6% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 8,340 shares of the company’s stock valued at $339,000 after acquiring an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 96.35% of the company’s stock.
A number of research analysts have weighed in on the stock. Dougherty & Co raised their target price on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Craig Hallum upped their price target on Omnicell from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Cantor Fitzgerald restated a “buy” rating and issued a $47.00 price target on shares of Omnicell in a research report on Tuesday, July 25th. Benchmark Co. upped their price target on Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. Finally, BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Omnicell currently has a consensus rating of “Buy” and an average target price of $51.57.
Omnicell, Inc. (NASDAQ OMCL) opened at 52.30 on Tuesday. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $52.70. The stock’s market capitalization is $1.96 billion. The firm’s 50-day moving average is $49.84 and its 200-day moving average is $44.39.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.38 earnings per share. On average, equities research analysts predict that Omnicell, Inc. will post $1.30 EPS for the current fiscal year.
In other Omnicell news, Chairman Randall A. Lipps sold 37,500 shares of the firm’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $46.00, for a total transaction of $1,725,000.00. Following the sale, the chairman now directly owns 196,551 shares of the company’s stock, valued at approximately $9,041,346. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Randall A. Lipps sold 40,000 shares of Omnicell stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $49.76, for a total transaction of $1,990,400.00. Following the sale, the chairman now owns 196,551 shares of the company’s stock, valued at $9,780,377.76. The disclosure for this sale can be found here. Insiders sold a total of 184,094 shares of company stock valued at $9,094,791 in the last three months. 3.77% of the stock is currently owned by corporate insiders.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.